·¨Ò½Ñ§½øÕ¹Óëʵ¼ù(µÚ¶þ¾í) Advances & Practices in Forensic Medicine 2
.
.
­ÄÔËðÉ˵ÄÑо¿½øÕ¹
.
ÁÎÖ¾¸Ö1 ÔøÕÑÊé1 Ö£ Á¢2 Ëï´óºê3
.
1»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§Ôº
.
2¹ãÖÝÊй«°²¾Ö½»¾¯Ö§¶Óʹʴ¦Àí¿Æ
.
3³É¶¼Êй«°²¾ÖÐ̾¯Ö§¶Ó
.
­ÄÔËðÉË£¨craniocerebral injury£©ÊÇ×î³£¼ûµÄ»úеÐÔËðÉË£¬Æä·¢ÉúÂʺÍËÀÍöÂʽö´ÎÓÚ°©Ö¢ºÍÐÄѪ¹Ü¼²²¡¶ø¾ÓµÚÈý룬ÔÚ±©Á¦ÐÔ
ËÀÍöÖЭÄÔËðÉ˵ÄËÀÍöÂʾÓÊ×λ¡£ËùÒÔ£¬Ñо¿Â­ÄÔËðÉ˵ķ¢Éú·¢Õ¹»úÀí¼°±ä»¯¹æÂÉ£¬ÎÞÂÛÊǶÔÁÙ´²
ҽѧ»ò·¨Ò½Ñ§£¬¶¼ÓÐ×ÅÊ®·ÖÖØÒªµÄÒâÒå¡£Ëæ×ÅÑо¿ÊֶεĸüУ¬Ðµļ¼Êõ²»¶Ï·¢Õ¹£¬Õâ·½ÃæµÄÑо¿
½øÕ¹ºÜ¿ì¡£ÎÒÃǽö¶Ô½üÄêÀ´Â­ÄÔËðÉË·½ÃæµÄÑо¿¶¯Ïò¡¢½øÕ¹×÷Ò»×ÛÊö¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.
.¡¡ Ò»¡¢ ÃÖÉ¢ÐÔÖáË÷ËðÉ˳ÉΪÑо¿Öصã

´«Í³µÄ­ÄÔËðÉËÓжàÖÖ·ÖÀà·½·¨£¬Èç°´ÖÂÉËÎïµÄÖÖÀà¡¢²¡³Ì³¤¶Ì¡¢ËðÉËÑÏÖØ³Ì¶È£¬Â­Ç»ÊÇ·ñÓëÍâ½ç
ÏàͨµÈµÈ½øÐзÖÀà¡£µ«ÊÇ£¬´«Í³·ÖÀà·¨µÄȱÏÝ£¬ÊǶԾÖÏÞÐÔ­ÄÔËðÉË£¬ÓÈÆäÊÇÄÔ´ìÁÑÉ˵Ĺý·ÖÇ¿µ÷¡£
×ÔCTÎÊÊÀÒÔÀ´£¬Ðí¶àÉñ¾­²¡Àí¡¢Éñ¾­Íâ¿Æ¹¤×÷Õß¶ÔÖØÐÍÍ·É˵ÄÄÔÉËÀàÐÍ£¬ÒѲ»Óô«Í³µÄÔ­·¢Óë¼Ì·¢
·ÖÀ࣬¶øÖ÷Òª¸ù¾ÝCTµÄ·¢ÏÖ½«ÖØÐÍÍ·ÉË·ÖΪ¾ÖÔîÐÔÓëÃÖÉ¢ÐÔÁ½´óÀà¡£¸ù¾ÝGennarelli[1-2]¼°AdamsJH[3]
µÈÈ˵Ĺ۵㣬¾ÖÏÞÐÔ£¨¾Ö²¿£©·ÇͶÉäÎïÐÔ­ÄÔËðÉËÕâÒ»´óÀàÄÔËðÉ˰üÀ¨£ºÄÔ´ìÁÑÉË¡¢Â­ÄÚѪÖס¢¸÷
ÖÖÀàÐ͵ļ̷¢ÐÔÄÔËðÉË¡£ÆäÖÐÓÖ·ÖΪ£ºÄԸɳöѪ»ò¹£ËÀ¡¢¸ÐȾ¡¢ÄÔÇÅËèÖÊ˺ÁѺʹ¹Ìå±úÓë­ÄÚÉñ
¾­µÄ˺ÍÑ¡£ÃÖÉ¢ÐÔ£¨ÃÖÂþ£©·ÇͶÉäÎïÐÔ­ÄÔËðÉËÕâÒ»´óÀàÄÔËðÉË£¬°üÀ¨ËÄÖÖÖ÷ÒªÐÎʽ£ºÃÖÉ¢ÐÔÖáË÷
ËðÉË£¨DAI£©,µÍÑõÐÔÄÔËðÉË£¨HBD£©,ÄÔÖ×ÕÍÓëÄÔË®Ö×,È«ÄÔ¶à·¢ÐÔСÔîÐÔ³öѪ¡£ ÆäÖÐ×îÖ÷ÒªµÄÊÇDAI¡£
ÓÉÓÚÈËÄÔÔÚÊܵ½±©Á¦×÷Óã¬ÐγÉËðÉËʱ£¬´ó¶àÊýÇé¿öϰéÓдóÄÔÔÚÍâ½ç±©Á¦×÷ÓÃϵÄÐýת¼ÓËÙÔ˶¯£¬
ËùÒÔÔÚÕâÖÖÇé¿öÏ·¢ÉúµÄ­ÄÔËðÉË£¬ÃÖÉ¢ÐÔÖáË÷ËðÉË(diffuse axonal injury,DAI)µÄ°é·¢Âʺܸߣ¬
¶øÇÒÒ»µ©·¢ÉúDAI£¬Æäºó¹ûÓÖÍùÍùÊ®·ÖÑÏÖØ¡£ÔÚ°ëÊýÒÔÉϵÄÑÏÖØÂ­ÄÔËðÉ˲¡È˺Í85%ÒÔÉÏÒò½»Í¨Ê¹Ê
µ¼ÖµÄÑÏÖØÂ­ÄÔËðÉ˲¡ÈËÖУ¬¶¼¿ÉÒÔ³öÏÖDAI£»¶øÇÒ£¬DAIµ¼ÖÂÁËËùÓÐÄÔËðÉË1/3µÄÈËËÀÍö£¬´ó¶àÊý´æ
»îµÄ²¡È˳ÊÖ²Îï״̬£¬Ï൱¶àµÄ´æ»î²¡ÈËÄÔ¹¦ÄÜÒì³£¡£GennarelliÈÏΪ£¬DAIºÍӲĤϳöѪÊÇ­ÄÔËðÉË
ÖÐÁ½¸ö×î³£¼ûµÄÖÂÃüÐÔËðÉË¡£ÔÚÎÞռλÐÔ²¡±äµÄ­ÄÔËðÉËÖУ¬DAI¿ÉÄÜÊÇ´´ÉËÐÔ»èÃÔµÄ×î³£¼ûÔ­Òò¡£
ͳ¼Æ±íÃ÷£¬ÔÚÓɽ»Í¨Ê¹ÊÒýÆðµÄÄÔËðÉËÖУ¬DAIµÄ·¢ÉúÂÊ×î¸ß£¬Õ¼85%£»ÔÚ×¹ÂäÉËÒýÆðµÄÄÔËðÉËÖУ¬
DAIµÄ·¢ÉúÂÊÕ¼µÚ¶þλ£¬Îª10%£»ÔÚ±©Á¦Ö±½Ó´ò»÷Í·²¿ÒýÆðµÄÄÔËðÉËÖУ¬DAIµÄ·¢ÉúÂÊÕ¼µÚÈý룬
Ϊ8%£»ÔÚÆäËûÔ­ÒòÒýÆðµÄÄÔËðÉËÖУ¬DAIµÄ·¢ÉúÂÊÕ¼1%[4]¡£

DAIÊÇ´óÄÔ°×ÖÊÉñ¾­ÏËάÖáË÷µÄËðÉË¡£Æä»ù±¾²¡±äÓÉÖáË÷µÄÃÖÉ¢ÐÔËðÉ˺ÍëÝëÕÌå¡¢ÄÔ¸ÉÉ϶˱³²àµÄ
¾ÖÔîÐÔ²¡Ëð×é³É¡£ÓÉÓÚÈ˵ĴóÄÔÔÚÕý³£Çé¿öÏÂÆäÃܶȲ¢·ÇÍêȫһÖ£¬ËùÒÔÔÚÐýת±©Á¦µÄ×÷ÓÃÏ£¬´ó
ÄԵİ×ÖÊ¡¢»ÒÖʵÈ×é·ÖÖ®¼ä²úÉú½Ï´óµÄ¼ôÁ¦¡¢À­Á¦¡¢Ñ¹Á¦£¬Ê¹Æä»¥Ïཻ´í¡¢Ç£À­¡¢¼·Ñ¹£¬Ôڴ˹ý³Ì
ÖУ¬Ï˳¤¶ø½á¹¹½ÏÈõµÄÖáË÷¸üÒ×Êܵ½ËðÉË¡£Ëæ×ŽǼÓËٶȵÄÔö´ó£¬ÖáË÷ËðÉ˵ÄÊýÁ¿Ôö¶à£¬·Ö²¼À©´ó£¬
¼´ÔÚ´óÄÔ°ëÇò¡¢¼äÄÔ¡¢ÉÏλÄԸɵİ×ÖÊÄÚÐγɹ㷺µÄËðÉË£¬²¢¿ÉºÏ²¢ÌØÊⲿ루ëÝëÕÌåºÍÉÏλÄÔ¸É
±³Íâ²à£©µÄ¾ÖÔîÐÔ²¡±ä£¬²úÉúÖØ¶ÈµÄÃÖÉ¢ÐÔÖáË÷ËðÉË£¨severe DAI£©£¬³öÏÖÉî¶È¶ø³Ö¾ÃµÄ»èÃÔ¡¢
È¥´óÄÔǿֱºÍ×ÔÖ÷Éñ¾­¹¦Äܲ»È«¡£Æä½á¹ûÊÇ£¬ÇáÕßÓпÉÄܵÃÒÔ»Ö¸´£¬ÖØÕß²»ÊÇËÀÍö¾ÍÊÇ´¦ÓÚÖ²Îﻯ
״̬»ò°éÑÏÖØ²¡²Ð¡£

AdamsµÈÈËÓÚ1989ÄêÌá³öÁËDAIµÄ²¡Àíѧ·Ö¼¶±ê×¼[5]¡£ÕâÒ»±ê×¼ÏÖÒѳÉΪÕï¶ÏDAIµÄ¹«Èϱê×¼¡£¹ØÓÚÖá
Ë÷µÄÃÖÉ¢ÐÔËðÉ˺ÍëÝëÕÌå¡¢ÄÔ¸ÉÉ϶˱³²àµÄ¾ÖÔîÐÔ²¡ËðÁ½ÖÖ²¡±äµÄÌØµãºÍ¹ý³Ì¾ßÌåÈçÏÂ[6]¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
1£®ÖáË÷µÄÃÖÉ¢ÐÔËðÉË Ö÷ÒªÊÇ´óÄÔ°ëÇò¡¢ëÝëÕÌå¡¢ÄԸɡ¢ÓÐʱ»¹ÓÐСÄÔ°×ÖʵÄÖáË÷ÊÜËðºóµÄ²¡±ä¡£ÊÜÉËÔçÆÚ£¬³¤ÏËάµÄÖáË÷
³Ê²»¹æÔò±ä´Ö¡¢ÖåñÞ£¬³Ê²¨ÀË×´£¬Æä¼äÓÐδÊÜÀÛµÄÕý³£µÄÏËά²¢ÐУ»¶ÌÏËά³Ê²»¹æÔòÓØ»Ø£»´Ö±äµÄÖá
Ë÷ΪÕý³£ÖáË÷µÄ3¡«5±¶ÒÔÉÏ£¬¶Ï¶Ë³Ê×¶ÐλòÕëÍ·×´¡£Ëæ×Å´æ»îʱ¼äÑÓ³¤£¬ÖáË÷±ä´Ö³ÊÄÒ×´¡¢Çò×´¡¢òò
ò½×´¡¢´®Öé×´£¬ÓеľíËõ³Ê»¡×´¡¢ÂÝÐý×´¡£¼ÌÖ®£¬ÖáË÷¶Ï¶Ë³ÊÇò×´£¬³ÆÎªÊÕËõÇò£¨retraction ball£©¡£ÊÕ
ËõÇò¿ÉÓëÖáË÷¶Ï¶ËÏàÁ¬»ò¹ÂÁ¢´æÔÚ£¬¹ã·º·Ö²¼ÓÚ´óÄÔ°×ÖÊ¡¢ÄԸɣ¬ÊÇÉñ¾­ÏËά˺ÁѵÄÖ¤¾ÝºÍÕï¶ÏDAI
µÄ²¡ÀíÐÎ̬ѧÒÀ¾Ý¡£

ÊÕËõÇò×÷ΪÖáË÷ËðÉ˵ĽÏÌØÒìÐÔ²¡±ä£¬×îÔçÓÉCajalÓÚ1982ÄêÌá³ö¡£ËûÈÏΪÆäÐγɻúÀíÊÇÖáË÷Êܵ½Ç£À­¡¢
˺ÁѺóµ¼ÖÂÖὬ»ý¾ÛÓÚÖáË÷µÄÔ¶²à¶Ï¶Ë¶øÐγɡ£VanezlsÓÃÒø½þȾɫ·¨¹Û²ìÊÕËõÇòµÄÐγɹý³Ì£¬ÈÏΪËð
É˺ó2h£¬ÖáË÷³ÊÃ÷ÏԵĽڶÎÐÔÔö´Ö¡¢ÊÕËõÇò²»Ã÷ÏÔ¡£É˺ó6¡«10h£¬ÄÒ×´Ôö´Ö¸üÃ÷ÏÔ£¬Ôö´ÖÏËά֮¼äµÄ
Éñ¾­ÏËά±äϸ£¬µ«ÈÔÁ¬Ðø£»É˺ó16h£¬Ö×Õ͵ÄÖáË÷¶Ï¶Ë³öÏÖÊÕËõÇò£¬Éñ¾­ÏËάÁ¬ÐøÐÔÖжϡ£É˺ó72h£¬
³öÏÖµäÐ͵ÄÊÕËõÇò¡£É˺óÊýÔÂÖÁÊýÄêËÀÍöÕߣ¬ÔÚÆäÄÔÄÚ½üºË¶ËµÄÖáË÷ÈԿɲé¼ûÊÕËõÇò¡£Ó¤¶ùµÄÖáË÷±È
³ÉÈËϸС£¬Î´ÍêÈ«Á×Ö¬»¯£¬ÊÕËõÇò²»Èç³ÉÈËÃ÷ÏÔ¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
2£®DAIµÄ¾ÖÔîÐÔËðÉË Í·²¿Êܱ©Á¦×÷ÓÃÐγÉÍ·ÉËʱ£¬ÓÉÓÚ¼ôÇÐÁ¦¡¢Ç£ÕÅÁ¦ºÍÐýתÁ¦µÄ×ÛºÏ×÷Ó㬳ýÐγÉÖáË÷µÄÃÖÉ¢ÐÔËðÉËÍ⣬
Ó¦Á¦¼Ó´óʱ¿ÉÑØÄÔµÄÖÐÖáÓÉ´óÄÔÏò×ÝÉîÀ©Õ¹£¬ÐγÉëÝëÕÌåºÍÄԸɵÄËðÉË¡£²¡±äÌØµãΪëÝëÕÌåºÍÄÔ¸ÉÓÐ
СÔîÐÔµÄ˺ÁÑ¡¢µã×´³öѪºÍƶѪÐÔ¹£ËÀ¡£ëÝëÕÌåµÄµäÐͱíÏÖΪС³öѪÔλÓÚÖÐÏßÒ»²à¡£²¡±ä×î³£¼û
ÓÚëÝëÕÌåϲ¿£¬²¢¿ÉÏòǰ¡¢ÏòºóÀ©Õ¹£¬Ò²¿ÉÀÛ¼°Í¸Ã÷¸ôºÍñ·Áþ²¿¡£ÄÔ¸ÉËðÉ˳£Î»ÓÚÄÔ¸É×첿±³Íâ²àÏó
ÏÞÇø£¨rostal dorsal lateral quardrant£©¼´ÄÔ¸ÉÉ϶˱³²à²¿Î»£¬³Ê¶àÊýСµã×´³öѪÔî¡£ÓеIJ¡Àý
ÈâÑÛ²¡±ä²»Ã÷ÏÔ£¬¾µÏ¿ɼû°×Öʼ«¶ÈÊèËɺͿÕÅݱäÐÔ¡£

ÃÖÉ¢ÐÔÖáË÷ËðÉËÔÚÄÔÄÚ²»Í¬½á¹¹·¢ÉúµÄƵÂÊΪ£ºÖÐÄÔ¡ªÄÔÇŶ¥¸Ç²¿95%£»ëÝëÕÌå92%£»µÚÈýÄÔÊÒÂöÂç´Ô
90%£»Ê¸×´ñ¼ÅÔ88%£¬³£ÓÉÓÚ»¬¶¯ÐÔÄÔ´ìÉËËùÖ£»º£Âí88%£»ÄÔÊÒÖÜΧ83%£»Í¸Ã÷¸ô80%£»²àÄÔÊÒÂöÂç
´Ô77%£»ñ·Áþ62%£»¿Û´ø»Ø61%£»ÊÓÇð56%£»ÖÐÄÔ¡ªÄÔÇÅ»ùµ×²¿38%£»»ùµ×½Ú17%¡£

3£®DAIµÄ²¡±ä¾­¹ýºÍ·¢Õ¹ ëÝëÕÌåºÍÄԸɵľÖÏÞÐÔ³öѪ²¡Ô¿ªÊ¼³Ê°µºìÉ«£¬ÊýÖܺó£¬ÓÉÓÚѪºìµ°°×·Ö½â£¬³öѪÔî³Êרɫ¡¢¿ÅÁ£
×´£¬¾µÏ¿ɼû²¡ÔîÇøÓоÞÊÉϸ°û£¬Æä°û½¬ÄÚº¬ÓÐרɫµÄº¬ÌúѪ»ÆËØ¿ÅÁ££¬¾Ö²¿×éÖ¯¿É³öÏÖ»µËÀ¡¢ÄÔÈí
»¯Ôî¡£¾­¹ýÊýÔ£¬½ºÖÊÏËάÔöÉúÐÞ¸´³Ê½ºÖÊñ£ºÛ¡£

ÖáË÷ËðÉ˲¡±ä¾­¹ýÊýÖÜÕߣ¬°×ÖÊÖпɼûµ½É¢ÔڵĽºÖÊϸ°û½á½Ú£¬Òà¿É¼ûµ½ÃÖÉ¢ÐÔ·ÇÌØÒìÐÔÐÇÐνºÖÊϸ
°ûÔöÉú¡£Í·ÉËºó´æ»îÊýÔÂÖÁÊýÄêÕ߿ɼûµ½°×ÖʳöÏÖWallerian±äÐÔ£¬´Ë±äÐÔÒÔÄÔ¸ÉÉÏÏÂÐÐÊø×îΪÃ÷ÏÔ£¬
³£·Ç¶Ô³ÆÐÔµØÓ°Ï쵽ƤÖʼ¹ËèÊø¡£ÓÉÓÚÖáË÷¶ÏÁѺóËèÇʱäÐÔ±À½â³ÉÖ¬µÎ£¬Òò´Ë£¬ÔÚÉñ¾­ÏËά¼ä¿É¼û¶à
ÊýÍÌÊÉÓÐÖ¬ÖÊ¿ÅÁ£µÄÅÝĭϸ°û¡£´ËÆÚÓÉÓÚÄÔ°×ÖÊÌå»ýήËõ£¬ëÝëÕÌå±ä±¡£¬ÏàÓ¦µØ¿É¼ûÄÔÊÒϵͳÀ©´ó¡£

Ëæ×ÅÃÖÉ¢ÐÔÖáË÷ËðÉË£¨DAI£©¸ÅÄîµÄÈ·¶¨ºÍÕï¶Ï±ê×¼Ìá³ö[5], ÒÔ¼°¶ÔÆä·¢Éú»úÀíµÄ²ûÃ÷£¬ÃÖÉ¢ÐÔ­ÄÔËðÉË
×÷Ϊһ´óÀà­ÄÔËðÉËÒÑΪԽÀ´Ô½¶àµÄÈËËù½ÓÊÜ¡£µ±Ç°£¬¹úÍâѧÕßÕý´Ó¸üÉîÈë¡¢¸ü±¾ÖʵĽǶÈÑо¿DAI¡£
ÔÚÎÒ¹ú,ÓÉÓÚ½üÄêÀ´¹«Â·½¨ÉèºÍ¹«Â·ÔËÊäÊÂÒµµÄ¾Þ´ó·¢Õ¹,µÀ·½»Í¨Ê¹ÊÈÕÒæÔö¶à,¹úÄÚÉæ¼°Õâ·½ÃæµÄÑÐ
¾¿Ò²Ô½À´Ô½¶à¡£DAIÒѳÉΪÑо¿µÄÖØµã¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
¶þ¡¢Â­ÄÔËðÉ˺óµÄѪÁ÷¶¯Á¦Ñ§ÌØÕ÷

ËðÉ˲»½ö½öÖ»¶ÔÄÔʵÖʲúÉúÆÆ»µ£¬Òà»áÔì³ÉÄÔѪÁ÷µÄÎÉÂÒ£¬¶øÇÒ£¬ËðÉËËùµ¼ÖµÄÄÔѪÁ÷Õϰ­ÔÚËðÉ˺ó
µÄ²¡Çé·¢Õ¹¹ý³ÌÖÐÓÐÖØÒª×÷Óᣵ«ÊÇ£¬³¤ÆÚÒÔÀ´£¬¶ÔÓÚ­ÄÔËðÉ˺óµÄÄÔѪÁ÷¶¯Á¦Ñ§ÎÉÂÒ¹æÂÉһֱûÓÐ
Ò»¸öÃ÷È·µÄ½áÂÛ¡£ÃÀ¹ú¼ÓÀû¸£ÄáÑÇ´óѧÂåÉ¼í¶·ÖУ£¨UCLA£©Â­ÄÔËðÉËÑо¿ÖÐÐÄ(BIRC)µÄMartin µÈÈ˶Դ˽øÐÐÁ˳¤´ï½üÊ®ÄêµÄÑо¿£¬ÔÚ×ÛºÏÔËÓÃ×îмì²âÊֶεĻù´¡ÉÏ£¬ÓÚ1997Äê³õ²½Ã÷È·ÁË­ÄÔËð
É˺óµÄѪÁ÷¶¯Á¦Ñ§ÌØÕ÷[7]¡£

ËûÃÇÈÏΪ£¬Â­ÄÔËðÉ˺ó£¬È«ÄÔµÄѪÁ÷¶¯Á¦Ñ§ÎÉÂÒ¿É·ÖΪÈý¸öʱÏà¡£ ʱÏà1£ºµÍ¹à×¢ÆÚ¡£´ËÆÚ·¢Éú
ÔÚËðÉ˺óµÚ0¡«24h£¬ÒÔÄÔѪÁ÷Á¿£¨CBF£©µÍÓÚÕý³£ÎªÌØÕ÷¡£´ËÆÚÄÔѪÁ÷Á¿µÍÓÚÕý³££¬Â­ÄÚ¹àעѹ
£¨CPP£¬ÖµÎªÑªÑ¹¼õȥ­ÄÚѹ£©Òì³£µÍ£¬´óÄÔÖж¯ÂöÁ÷ËÙ£¨VMCA£©Õý³££¬ÄÔ°ëÇòÖ¸Êý£¨HI,ֵΪ
VMCA/VEC-MCA£¬·´Ó³ÄÔѪ¹Ü¾·Âγ̶ȣ©Õý³££¬ÄÔ¶¯¾²ÂöÑõ·Öѹ²î£¨AVDO2£©Õý³££¬µ«ÊÇÄÔÑõ´úл
ÂÊÔÚ´ËÆÚ½ÏÕý³£Ï½µ50%£¬¶øÇÒÔÚµÚ¶þ¡¢µÚÈýÆÚ³ÖÐøÏ½µ¡£ ʱÏà2£º³äѪÆÚ¡£´ËÆÚ·¢ÉúÔÚËðÉË
ºóµÚ1¡«3Ì죬ÒÔÄÔѪÁ÷Á¿£¨CBF£©Ôö¼ÓÎªÌØÕ÷¡£´ËÆÚÄÔѪÁ÷Á¿Ôö¼Ó¿É´ï×î´óÖµ£¬Â­ÄÚѹ£¨ICP£©Éý¸ß£¬
´óÄÔÖж¯ÂöÁ÷ËÙÉÏÉý£¬ÄÔ°ëÇòÖ¸ÊýÓÐËùÉÏÉý£¬ÄÔ¶¯¾²ÂöÑõ·Öѹ²îÃ÷ÏÔϽµ¡£Ê±Ïà3£ºÑª¹Ü¾·ÂÎÆÚ¡£
´ËÆÚ·¢ÉúÔÚËðÉ˺óµÚ4¡«15Ì죬ÒÔÄÔ°ëÇòÖ¸ÊýÃ÷ÏÔÔö¼ÓÎªÌØÕ÷¡£´ËÆÚÄÔѪÁ÷Á¿Ï½µ£¬´óÄÔÖж¯ÂöÁ÷
ËÙ½øÒ»²½Ôö¼Ó£¬ÄÔ¶¯¾²ÂöÑõ·Öѹ²î½ÏʱÏà2ÓÐËù»ØÉý£¬ÄÔ°ëÇòÖ¸ÊýÔòÓÐÒ»¸öÃ÷ÏÔµÄÔö¼Ó¡£
ÕâÊÇÆù½ñΪֹµÚÒ»¸öÁªºÏÔËÓÃÄÔѪÁ÷Á¿µÄ¡¢´úлµÄ¼ì²âÊֶκ;­Â­¶àÆÕÀÕ£¨TCD£©¼°ÆäËüÊÖ¶ÎÀ´¹Û²ì
­ÄÔËðÉ˺óµÄѪÁ÷±ä»¯ÌصãºÍʱ¼ä¹ý³ÌµÄÑо¿¡£¾¡¹ÜËüÖ»±íÃ÷­ÄÔËðÉ˺óÈ«ÄÔµÄѪÁ÷¶¯Á¦Ñ§ÌØµã¶ø·Ç
ijһ¾Ö²¿µÄѪÁ÷¸Ä±ä£¬µ«ÊÇÆä½áÂÛÒà×ãÒÔ±íÃ÷­ÄÔËðÉ˵ÄÑо¿½øÈëÁËÒ»¸öеÄÀï³Ì±®¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
Èý¡¢ÔÚÉñ¾­²¡Àí·½Ãæ£¬Â­ÄÔËðÉ˼ì²âÖ¸±ê·¶Î§À©´ó

Ëæ×Å×éÖ¯»¯Ñ§·½·¨µÄÍêÉÆºÍ·Ö×ÓÉúÎïѧ¡¢·Ö×Ó²¡Àíѧ·½·¨µÄ·¢Õ¹£¬Â­ÄÔËðÉ˼ì²âÖ¸±ê´ó´óÔö¼Ó¡£Ä¿Ç°£¬
¶ÔÄÔËðÉ˲¡Àí¸Ä±äµÄ¼ì²âÄÚÈÝ£¬¿ÉÒÔ·ÖΪÁ½´óÀࣺһÀàÊǶԺËËáµÄ¼ì²â£¬Ò»°ãÊǶ԰©»ùÒòµÄ¼ì²â£¬
°üÀ¨c-fos[8-9]¡¢hsp70¡¢p53µÈ£¬ÒÔ¼°¶ÔmRNAµÄ¼ì²â£»ÁíÒ»ÀàÊÇ¶ÔÆäËûϸ°û³É·ÖµÄ¼ì²â£¬Ö÷ÒªÊǶԵ°°×
µÄ¼ì²â£¬°üÀ¨Éñ¾­Ï¸Ë¿µ°°×(NFP)£¬S-100µ°°×£¬½ºÖÊϸ˿ËáÐÔµ°°×(GFAP)£¬Éñ¾­ÔªÌØÒìÐÔÏ©´¼»¯Ã¸
(NSE)£¬Êȸõ¿ÅÁ£µ°°×£¨Chromogranin A£©,Í»´¥ËØÓÖ³ÆÍ»´¥ÄÒÅݵ°°×(Synaptophsin,SY),΢¹Ü
Ïà¹Øµ°°×£¨MAPs£©,µí·ÛÑùǰÌåµ°°×£¨APP£©,Éñ¾­Éú³¤Òò×Ó(NGF)ºÍ¶àÖÖ¼¤Ëصȡ£ËäÈ»×î½ü¼¸ÄêÀ´ÓÐ
Ñо¿Õß¶ÔÄÔËðÉ˺óÄÔ×éÖ¯±í´ïµÄÑ×ÐÔÒò×Ó½øÐмì²â£¬Èç¼ì²â°×ϸ°û½éËØ-1b (interleukin-1b £¬IL-1b )¡¢Ö×Áö»µËÀÒò×Óa £¨tumor necrosis factor-a ,TNF-a £©¡¢¸ÉÈÅËØg £¨interferon-g ,IF-g £©¡¢ÏËάĸϸ°ûÉú³¤
Òò×Ó£¨fibroblast growth factor,FGF£©µÈ,µ«¾ÍÆäʵÖʶøÑÔ£¬ÈÔÊǶԵ°°×Öʵļì²â£¬ÕâÁ½ÀàÖ¸±êÖ®ºÍ
Óм¸°ÙÖÖÉõÖÁÉÏǧÖÖÖ®¶à¡£µ«ÊÇ£¬ÔÚÒ»¸öʵÑéÖÐÑо¿ÕßÍùÍù½«ºËËáÓëµ°°×½áºÏÆðÀ´Ñо¿¶ø²»ÊǹÂÁ¢
µÄÑо¿Ä³Ò»Ïî»òijһÀàÖ¸±ê¡£ÎÒÃÇÑ¡ÔñÒÔÏÂÖ¸±ê½øÐмòÒªÐðÊö¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
Éñ¾­Ï¸Ë¿µ°°×£¨neurofilament protein,NFP£©[10-13]

Éñ¾­Ï¸Ë¿ÊÇÉñ¾­Ôª°ûÖÊÄÚÖмäË¿µÄÒ»ÖÖ£¬Ö±¾¶Ô¼Îª10nm£¬³£¼¯ºÏ³ÉÊø¡£ËüÓëÖ±¾¶Ô¼25nmµÄ΢¹Ü½»²æ
ÅÅÁгÉÍø£¬ÉìÈëÊ÷Í»ºÍÖáÍ»ÄÚ£¬¹¹³ÉÉñ¾­ÔªµÄ¹Ç¼Ü£¬²ÎÓëÎïÖÊÔËÊä¡£ÔÚÒøÈ¾É«ÇÐÆ¬ÖУ¬Éñ¾­Ë¿ºÍ΢
¹Ü³ÊרºÚɫϸ˿£¬ÓÖ³ÆÉñ¾­Ô­ÏËά£¨ neurofibri1£©¡£ Éñ¾­Ï¸Ë¿µ°°×ÊÇÓÉÈý¸öÑǵ¥Î»×é³ÉµÄ
¶à¾ÛÌ壬·Ö±ðΪ200KDµÄÑǵ¥Î»¼´ÖØÉñ¾­Ï¸Ë¿µ°°×£¨heavy neurofilament protein,Nf--H£©¡¢
150-170KdµÄÑǵ¥Î»¼´ÖÐÉñ¾­Ï¸Ë¿µ°°×£¨medium neurofilament protein,Nf--M£©ºÍ68KdµÄÑǵ¥Î»¼´ÇáÉñ
¾­Ï¸Ë¿µ°°×£¨light neurofilament protein,Nf--L)¡£Ê󵥿Ë¡¿¹ÌåSMI32¿ÉÒÔ¶ÔNf--HºÍNf--MµÄ·ÇÁ×Ëữ
Ƭ¶Î·¢Éú·´Ó¦£»SMI--31¿ÉÒÔ¶ÔNf--HºÍNf--MµÄÁ×ËữƬ¶Î·¢Éú·´Ó¦£»SMI--33Ò²¿ÉÒÔ¶ÔNf--HºÍNf--M
·¢Éú·´Ó¦¡£¿¹ÌåNR4¿ÉÒÔ¶ÔNf--L·¢Éú·´Ó¦¡£¶Ô´ËÑо¿±íÃ÷£¬¶ÔÈËÄÔÇÐÆ¬£¬Ó¦Óÿ¹68kdÑǵ¥Î»µÄ¿¹ÌåЧ
¹û×îºÃ£¬´ËʱÉñ¾­Ôª×ÅÉ«Çå³þ£¬±³¾°È¾É«¼«µ­¡£Grady MS·¢ÏÖ£¬ÔÚDAI·¢Éúºó£¬ÒÔNfÑôÐÔ
ÎªÌØÕ÷µÄÖáË÷ÊÕËõÇò·Ö²¼ÔÚ¶îÒ¶¡¢¶¥Ò¶¡¢ò¨Ò¶µÄ±³²àµÄ°×ÖÊ£¯»ÒÖÊÁªºÏ´¦µÄÄÔ»ØáÕÖкͲàÄÔÊÒ±ßÔµ¡£
ÔøÓÐʵÑéÏÔʾ£¬ÓëDAIÏà¹ØµÄƤÖÊ3²ãºÍ5²ãµÄ×¶ÌåÉñ¾­ÔªµÄ°ûÖÊÃܶÈÔö¸ß£¬Í¬Ê±´Ë´¦SMI31Ç¿ÑôÐÔ¡£
ÓëÒøÈ¾É«Ïà±È£¬Ó¦Óÿ¹NfµÄ¿¹Ìå¿ÉÒÔÔÚËðÉ˺ó6hÄÚ·¢ÏÖÖáË÷µÄ·´Ó¦ÐԸı䣬¶øÒøÈ¾É« ÒªÓÐËù·¢ÏÖÖÁÉÙÊÇÔÚ24hºó¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
½ºÖÊϸ˿ËáÐÔµ°°×£¨glial fibrillary acidic protein,GFAP£©[14-18]

ÔÚÍ˱äÐÔ¼²²¡»òÍâÉËËùÖµÄÖÐÊàÉñ¾­ÏµÍ³µÄ×éÖ¯ÆÆ»µÖУ¬·´Ó¦ÐԵĽºÖÊÔöÉúÊÇÒ»¸öÆÕ±éÏÖÏó£»ÔÚÑÏÖØ
ËðÉË»ò¼²²¡µÄ²¡ÀýÖУ¬ÔöÉú·´Ó¦µÄÐÇÐνºÖÊϸ°ûÔö¼ÓÁ˽ºÖÊϸ˿µÄÊýÁ¿£¬ÐγɽºÖÊñ£ºÛ¡£´Ë²»¿ÉÄæµÄ
½á¹¹¸Ä±ä±»ÈÏΪ¶ÔÉñ¾­ÔªµÄÍ˱䡢ËèÇÊÔÙÐγɺ͹¦Äָܻ´Óв»Á¼Ó°Ïì¡£

¹ýÈ¥£¬¶Ô·´Ó¦ÐÔ½ºÖÊÔöÉúµÄÑо¿Ö÷ÒªÊÇ»ùÓÚÐÎ̬ѧ֤¾Ý¡£Ëæ×ÅÒ»¸ö49Kdµ°°×£¨¼´GFAP£©µÄ·¢ÏÖ£¬Ëü±»
ÈÏΪÊǽºÖÊϸ˿µÄÖ÷Òª³É·Ö¡£Í¨¹ýʹÓÃÕë¶ÔÕâÖÖµ°°×ÌØÒìÐÔ¿¹ÌåµÄÃâÒß×éÖ¯·½·¨½øÐÐÑо¿£¬Ê¹²úÉú·´Ó¦
µÄÐÇÐÎϸ°ûµÃµ½×î´óÏ޶ȵIJûÃ÷¡£ÔÚ¶³ÉË¡¢´Ì´´¡¢Öж¾ËðÉ˺ÍʵÑéÐÔ×ÔÌåÃâÒßÐÔÄÔĤÑ×£¨EAE£©µÈ¼¸¸ö
Éæ¼°½ºÖÊÔöÉúµÄ¶¯ÎïʵÑéÄ£ÐÍÖУ¬¾ù·¢ÏÖGFAPµÄÃâÒß»îÐÔÔö¼Ó¡£

ͨ¹ýÓ¦ÓÃÃâÒß»¯Ñ§Ó¡¼£·¨£¬·¢ÏÖGFAPµÄÁ¿ÔÚ»¼EAEµÄLewisÊóµÄ¼¹ËèÖÐÓÐÁËÃ÷ÏÔÔö¼Ó¡ª¡ªËüʼÓÚ¼Þ½Ó
£¨»ò¸ÐȾ£©ºó10¡«12Ì죬ÖÁÉÙ³ÖÐøÖÁ65dpi£¨days postinoculation£¬¼Þ½Ó»ò¸ÐȾºóÌìÊý£©¡£Õâ¸öÐÇÐÎ
ϸ°û·´Ó¦±é·¢ÓÚ¼¹Ë裬ÓëÑ×ÐÔËðÉ˲¿Î»Î޹ء£È»¶ø£¬ÔÚ13¡«18dpiÕâÒ»ÔöÇ¿ÃâÒßȾ×îÇ¿µÄʱÆÚȴδ¼ì²â
µ½ÓÐÃ÷ÏÔµÄGFAPº¬Á¿Ôö¼Ó¡£½øÒ»²½Ñо¿Ö¤Ã÷£¬¼¹ËèÖÐGFAPº¬Á¿Öð²½Ôö¼Ó£¬ËæÊ±¶ø±ä£ºÔÚ35dpi֮ǰ´ï
µ½¶ÔÕÕ×éµÄ1.5¡«2±¶£¬Ö±µ½65dpiʱÈÔ³ÖÐøÉý¸ß¡£Òò´ËÔÚÕâ¸ö¶¯ÎïÄ£ÐÍÖÐGFAPº¬Á¿ºÍÃâÒß»îÐÔÓÐÒ»¸öÑÓ
³¤µÄ³ÖÐøÔö¼Ó¡ª¡ªËüÔ¶ÔÚÁÙ´²Ö¢×´Ö®ºó£¬¶ø´ËʱÑ×ÐÔ·´Ó¦ºÍѪ¹Üͨ͸ÐÔÒÑÃ÷ÏÔϽµ¡£Æä×Ѱ³£µÄÌØµã
ÊÇÔÚ¼²²¡¹ý³ÌµÄÔçÆÚ½×¶ÎGFAPº¬Á¿Ôö¼ÓµÄÇãÏò¡£ 1990Ä꣬Hozumi IµÈÈ˶ÔÄÔ´Ì´´ºóµÄGFAPÉú»¯ºÍ
ÃâÒßϸ°û»¯Ñ§½øÐÐÑо¿£¬·¢ÏÖÔÚÕý³£¶¯ÎïÄÔÖУ¬GFAPÑôÐÔ½ö¼ûÓÚѪ¹ÜÖÜΧ¡£ÔÚ´Ì´´ºó3h£¬GFAPÑôÐÔ
ϸ°ûÖ÷Òª¼ûÓÚÄÔÆ¤ÖÊÉϲ¿£¬ÆäËû²¿Î»½Ï¼ÙÊÖÊõ×é¼õÉÙ¡£´Ì´´ºó6h£¬GFAPÑôÐÔϸ°ûÔÚÉ˿ڸ½½ü¸üÉÙ¡£
É˺ó12h£¬GFAPÑôÐÔϸ°ûÔÚÉ˿ڸ½½üÔö¼Ó£¬ÔÚÉ˿ں󲿿ÉÒÔ¼ûµ½¡£É˺ó1Ì죬GFAPÑôÐÔϸ°ûÔö¼Ó¿É¼û
ÓÚÄÔËùÓв¿Î»£¬ÓÈÆäÊÇÆ¤ÖʲãºÍº£Âí¡£É˺ó3Ì죬¼¯Öжø¹ã·ºµÄGFAPÑôÐÔϸ°û³öÏÖÔÚÄÔÆ¤ÖÊ¡¢ëÝëÕÌå¡¢
¿Û´ø»Ø¡¢ÍâÄÒ¡¢ÄÚÄÒ¡¢ÊÓÊø¡¢ÓÈÆäÊǺ£Âí¡£É˺ó5¡«7Ì죬ÉË¿ÚÖÜΧϸ°ûÃ÷ÏÔÔö¼Ó£¬Ñ×ϸ°û¸½½üÄÔ×éÖ¯
¿Õ¶´Ðγɣ¬½ºÖÊϸ°ûÔÚº£Âí²¿ÔöÉúÃ÷ÏÔ£¬GFAPÇ¿ÑôÐÔ£¬×ÜGFAPÊǼÙÊÖÊõ×éµÄ2±¶¡£É˺ó14¡«21Ì죬
É˺ó¿Õ¶´À©´ó£¬Ñ×ϸ°ûÊýÁ¿Ôö¼Ó£¬GFAPÊǶÔÕÕ×éµÄ117%¡£ Hozumi IµÈÈËËæ¼´¶ÔÊóÄÔ´Ì´´ºóµÄ
GFAPmRNA ˮƽ±ä»¯Çé¿ö½øÐÐÁËÑо¿¡£ËûÃÇ·¢ÏÖÓë¶ÔÕÕ×éÏà±È£¬ÊóÄÔGFAPmRNAÓнÏС
Á¿¶øÎÞͳ¼ÆÑ§ÒâÒåµÄÔö¼Ó¡£´Ì´´ºó12h£¬GFAPmRNAÔö¼ÓÁË5±¶£»´Ó´Ì´´ºó12hÖÁ5Ì죬GFAPmRNA
Óë¶ÔÕÕ×éÏà±È±£³ÖÁËÒ»¸ö3.5±¶µ½5±¶µÄÔö¼Ó£»´Ì´´ºó7Ì죬GFAPmRNAϽµµ½¶ÔÕÕ×éµÄ2.5±¶£»´Ì´´ºó
21Ì죬GFAPmRNAϽµµ½¶ÔÕÕ×éµÄ1.5±¶¡£×ÔHozumi IµÈÈËÒÔºó£¬ÓÖÓн϶à×÷Õß¶Ô
¸÷ÖÖÇé¿öÏÂGFAPµÄ±ä»¯×÷ÁËÑо¿£¬½áÂÛ»ù±¾ÏàËÆ¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
Éñ¾­Éú³¤Òò×Ó£¨nerve growth factor, NGF£©[19-22]

NGFµÄ·¢ÏÖÊÇÉñ¾­ÉúÎïѧ·¢Õ¹µÄ±êÖ¾¡£
1948Ä꣬Buedeer·¢ÏÖ¼¦Åߵı³²à¸ùÉñ¾­½ÚÏòÒ»ÒÆÈ뼦Ìå±ÚµÄÊóÈâÁö180£¨mouse sarcoma 180£©Éú³¤³öÖáÍ»¡£Levi-Montalcini & HamburgerµÈÈËÓÚ1951Äê¡¢1953Äê·¢ÏÖ½»¸ÐÉñ¾­½Ú
Ò²²ÎÓëÉñ¾­ÏòÖ×ÁöµÄÉú³¤¹ý³Ì£¬²¢±íÃ÷´Ë½á¹ûÊÇÓÉÓÚÈâÁö²úÉúÒ»ÖÖÌØÒìµÄÉú³¤Òò×Ó×÷ÓõĽá¹û¡£
Õâ¸öÉú³¤Òò×Ó¾ÍÊÇÉñ¾­Éú³¤Òò×Ó¡£ 1960Ä꣬Ñо¿ÈËÔ±·¢ÏÖÊóµÄò¢ÏÂÏÙÖÐÓиßŨ¶ÈµÄNGF£¬
²¢Ã÷È·ËüÊÇÒ»ÖÖµ°°×¡£1967Äê¡¢1968ÄêÏà¼Ì·ÖÀë³ö´Ëµ°°×¡£ºóÀ´£¬ÈËÃÇ·¢ÏÖÁ˸ü¶àµÄÀàËÆÓÚNGF
µÄÉñ¾­ÓªÑøµ°°×£¨neurotrophins, NTs£©¡£

NGFÓÐÁ½ÖÖÐÎʽ£º¸ß·Ö×ÓÁ¿µÄÐÎʽ¼´7SNGF¸´ºÏÌ壬ÒÔ¼°2.5SNGF¡£7SNGFÊÇNGFµÄ»îÐÔÐÎʽ¡£
7SNGFµÄ×é³ÉÊÇa 2b g 2Zn2+£¬ÆäÖÐa ¡¢b ¡¢g ¾ùΪÆäÑǵ¥Î»¡£b Ñǵ¥Î»ÊÇÆä»ù±¾³É·Ö£¬
ÓëNGFµÄÉúÎï»îÐÔÏà¹Ø¡£Ëü×î³õÊÇÒÔǰÌåµ°°×ÐÎʽ±»ºÏ³É£¬Ëæºóͨ¹ýøÐÞÊζø´ïµ½³ÉÊì״̬¡£³ÉÊìµÄb NGFÊÇÓÉÏàͬµÄ¡¢¾ùº¬·Ç¹²¼Û½áºÏµÄ118¸ö°±»ùËáµÄÁ½Ìõ°±»ùËáÁ´×é³ÉµÄ¶þ¾ÛÌå¡£ËäÈ»¶þ¾ÛÌåÐÎʽÊÇb NGFµÄÖ÷ÒªÉúÀíѧģʽ£¬µ«ÊÇÆäµ¥ÌåÒ²ÓÐÉú³¤´Ù½ø»îÐÔ¡£¶Ôb Ñǵ¥Î»µÄ°±»ùËáÐòÁзÖÎö±íÃ÷£¬
¸ÃÁ´ÓÐÁù¸ö°ëë×°±Ëá²Ð»ù£¬Ê¹ÆäÐγÉÒ»¸öº¬ÓÐÈý¸ö¶þÁò¼üµÄÈý¼¶½á¹¹£»ÈκÎÒ»¸ö¶þÁò¼ü¶ÏÁÑ£¬¾ù¿Éµ¼
Ö¶þ¾ÛÌåµ¥Ìå»îÐÔÍêȫɥʧ¡£g Ñǵ¥Î»ÔòÏÔʾ³öת°±ÌØÒìµÄõ¥ëÄø»îÐÔ¡£°±»ùËáÐòÁзÖÎö±íÃ÷£¬g Ñǵ¥Î»ÊÇÏÙÌåѪ¹ÜÊæ»ºËØ£¨glandular kallikrein£©¼Ò×åÖеÄÒ»Öֳɷ֣¬ÒÔË¿°±Ëáµ°°×ÈÜøÄÜÁ¦ÎªÌØÕ÷¡£g Ñǵ¥Î»´Ó·Ç»î»¯µÄÐÎʽµ½»î»¯ÐÎʽµÄ¹ý³ÌÖУ¬ÓÉÓÚÊܵ½ÁíÒ»¸öÏÙÌåѪ¹ÜÊæ»ºËصÄ×÷Ó㬶øÐγÉÁ˲»Í¬
µÄ°±»ùËáÁ´£¬ÕâЩÁ´Í¨¹ý¶þÁò¼üÏà½Ó£¬ÐγÉ2¡«3¸ög Ñǵ¥Î»¡£g Ñǵ¥Î»µÄÒìÔ´ÐÔʹÆäµÈµçµã·¶Î§
·Ö²¼ÔÚ5.2¡«5.8Ö®¼ä¡£ÓÐÖ¤¾Ý±íÃ÷£¬g Ñǵ¥Î»ÊÇ´Ób NGFǰÌ壨pro-beta-NGF£©ÑÝ±ä¶øÀ´µÄ¡£g Ñǵ¥Î»¶Ôb NGFÓе÷¿Ø×÷Ó㬲¢±£»¤³ÉÊìµÄb Ñǵ¥Î»ÃâÊÜÆäËûø½µ½â¡£a Ñǵ¥Î»µÈµçÖµÔÚ4.1¡«4.6Ö®¼ä£¬
ÊÇ7S-NGFÖÐ×î¾ßËáÐԵijɷ֡£Èçͬg Ñǵ¥Î»Ò»Ñù£¬a NGFÓëÆäËûÏÙÌåѪ¹ÜÊæ»ºËØÓи߶ȵÄͬԴÐÔ
£¨78%Óëg Ñǵ¥Î»Í¬Ô´£©¡£a Ñǵ¥Î»Ç°Ìåµ°°×µÄ·Ö»¯¹ý³ÌÒർÖÂÁËa Ñǵ¥Î»µÄһЩÒìÔ´³É·Ö¹²´æ¡£È»¶ø£¬
ÊͷųöµÄa Ñǵ¥Î»ÔÚÆäÐγɹý³ÌÖÐÔò²»¾ßÓÐø»îÐÔ¡£a Ñǵ¥Î»±»ÈÏΪÓб£»¤NGFÃâÊÜø½µ½â¡¢µ÷½Úb ºÍg Ñǵ¥Î»»îÐԵȹ¦ÄÜ¡£Zn2+ÓÐά³Ö7SNGFÎȶ¨ÐÔµÄÖØÒª×÷Óã¬ÒàÊÇÆäÖ÷Òª³É·Ö¡£

2.5SNGFÊÇb NGFµÄÁíÒ»ÖÖÐÎʽ£¬ÒàÊÇ´ÓÊóò¢ÏÂÏÙ·ÖÀë³ö¡£2.5NGFÓë-b NGFÓÐÃ÷ÏÔµÄͬԴÐÔ£¬
µ«ÆäN-Ä©¶ËºÍC-Ä©¶Ë¶¼ÓÐËùÐÞÊΡ£ÏÖÔÚÈÏΪ£¬2.5NGFµÄÐγÉÊÇ7S¸´ºÏÌåÀë½â³ö¦ÂÑǵ¥Î»ºó£¬Ëæ¼´¸Ã
±»ÊͷųöµÄµ°°×ͨ¹ýµ°°×ÈÜ½â¶øÐγɡ£

ÔÚ·¢ÏÖNGFºó£¬1978Äê¡¢1980ÄêÏà¼Ì·¢ÏÖÓëNGFÓÐÏàͬ×÷Ó㬸߶ÈͬԴµÄÄÔÔ´ÐÔÉñ¾­ÓªÑøµ°°×
£¨Brain-derived neurotrophic factor, BDNF£©¡£Ëæºó£¬Éñ¾­ÓªÑøµ°°×-3£¨neurotrophin-3, NT-3£©¡¢Éñ¾­ÓªÑøµ°°×-4£¨NT-4£©¡¢Éñ¾­ÓªÑøµ°°×-5£¨NT-5£©µÈÏà¼Ì±»·¢ÏÖ¡£

NGFÔÚÍâÖÜÉñ¾­ÏµÍ³ÖеÄ×÷Óã¬Ö÷ÒªÊÇÑ¡ÔñÐÔµØ×÷ÓÃÓÚÉöÉÏÏÙËØÄÜÉñ¾­ÔªºÍµÚÒ»¸Ð¾õÉñ¾­Ôª¡£ÕâЩϸ
°ûÔÚÊܵ½NGF×÷ÓÃʱ·Ö»¯£¬ÖáÍ»ÑÓÉ죬ӰÏì¶ù²è·Ó°·µÄº¬³É£¬ÈçÓ°ÏìÉñ¾­ëĺϳÉø¡£ÔÚÖÐÊ࣬NGFµÄ
ÖØÒª°Ðϸ°ûÊǵ¨¼îÄÜÉñ¾­Ôª¡£ÍâÔ´ÐÔµÄNGF¿ÉÒÔʹÕâЩ³É·Ö½þÈóÄÜÁ¦Ôö¼Ó£¬´æ»îÆÚÑÓ³¤¡£ÊµÑé½á¹û»¹
ÏÔʾ£¬ÐÂÉú¶¯ÎïÄ£ÐÍ»ò³ÉÄ궯ÎïµÄÄ£ÐÍÖУ¬¿¹NGF¿¹ÑªÇå¶ÔNGFÃô¸ÐµÄÉñ¾­ÔªµÄ·¢Éú¡¢·Ö»¯ºÍ´æ»î¾ù
ÓÐ×è¶ÏЧ¹û¡£NGFµÄ×÷Óã¬ÊÇͨ¹ýÓëÊÜÌå½áºÏÀ´Æô¶¯°ûÄÚϵÁз´Ó¦¹ý³Ì¡£Éñ¾­ÓªÑøµ°°×ÊÜÌå°üÀ¨75K
DaµÄµÍ½áºÏÁ¦ÊÜÌ壬140KDaµÄÔ­°©»ùÒòTrk±àÂëµÄµ°°×ÊÜÌ壬Trk-BÊÜÌåºÍTrk-CÊÜÌå¡£NGF¿ÉÒÔÓë75K
DaµÄÊÜÌåºÍTrkµ°°×ÊÜÌå·¢Éú½áºÏ¡£Ä¿Ç°ÈÏΪNGFÓëTrkµ°°×µÄÇ׺ÍÁ¦½Ï´ó£¬Óë75KDaµÄÊÜÌåÇ׺ÍÁ¦½ÏµÍ¡£
¶þÕßÈç¹ûͬʱ¾ùÓëNGF½áºÏ£¬ÔòÆäÇ׺ÍÁ¦´ó´ó³¬¹ýÈκε¥Ò»ÊÜÌåÓëNGFµÄ½áºÏ¡£Éñ¾­ÓªÑøµ°°×ÓëÊÜÌå
½áºÏºó£¬¼ÓËÙÀÒ°±ËáÁ×Ëữ£¬ÓÖµ¼ÖÂIBºÍDAGµÄѸËÙÔö¼Ó£¬Í¬Ê±¼¤»îMAPKRK£¬µ¼ÖÂMAPµÄºÏ³É£¬
×îÖÕÖºËÄڳɷֵıí´ï¡£Æä×÷ÓûúÀíÏ൱¸´ÔÓ¡£

NGF»ùÒò±í´ïºÍºÏ³É·¢ÉúÔÚ¶à¸ö²¿Î»£¬ÔÚÍâÖÜ£¬ÔÚÊ侫¹Ü¡¢ÐÄ¡¢ºçĤ¡¢Æ¤·ô¡¢µ¨ÄÒ¡¢×ø¹ÇÉñ¾­ºÍò¢ÏÂÏÙ
¾ù¿É¼ì¼û±í´ï¡£ÔÚÖÐÊ࣬NGFÑôÐԵĵ¨¼îÄÜÉñ¾­Ôª·Ö²¼ÔÚº£Âí£¬Æ¤ÖÊ£¬Öмä¸ô£¬Broca¶Ô½Ç¶Î£¬Meynert
»ùµ×ºË£¬ÐáÇò£¬ÎÆ×´ÌåµÄÖмäÉñ¾­Ôª¡£×î´óÊýÁ¿µÄNGFmRNA¶¨Î»ÓÚº£ÂíºÍƤÖÊ¡£

×î½ü·¢ÏÖ£¬ÔÚ²»Í¬ÀàÐ͵Ä­ÄÔËðÉ˺ó£¬NGFˮƽÓÐÑÓ³ÙÐÔÉý¸ß¡£Steven T. Dekosky·¢ÏÖ£¬ÔÚÖØÎïÂäÌå´ò»÷Ä£ÐÍÖУ¬NGFÔÚµÚËÄÌìÉý¸ßµ½4±¶£¬µ½µÚ°ËÌìϽµµ½3±¶µÄˮƽ£¬µ½µÚ15Ìì
×óÓÒÈÔά³ÖÓÚ3±¶¶àµÄˮƽ£»¶øÔÚÆøÑ¹´ò»÷×°ÖõÄÄ£ÐÍÖУ¬ËðÉ˺óÖ±ÖÁµÚ8Ì죬NGFÒ»Ö±³ÖÐøÔö¼ÓÖÁÕý³£
µÄ1.8±¶¡£×÷ÕßÃÇÈÏΪ£¬¾¡¹ÜNGFÓÐÐí¶à×÷Ó㬵«ÊÇNGFµÄÔö¶àÊÇÄÔËðÉ˺ó¾ÞÊÉϸ°û¡¢Ð¡½ºÖÊϸ°û¡¢ÐÇÐÎ
ϸ°ûÊͷųöµÄÑ×ÐÔÒò×Ó£¬ÓÈÆäÊÇIL-1×÷ÓõĽá¹û¡£ÔÚIL-1µÄ×÷ÓÃÏ£¬µ¼ÖÂNGFµÄ²úÉú¡¢Éý¸ß¡£

.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡
΢¹ÜÏà¹Øµ°°×£¨microtubule asssociated protein-2,MAP-2£©[23-25]

΢¹ÜÊǹ¹³ÉÉñ¾­ÔªÏ¸°û¹Ç¼ÜµÄÖ÷Òª³É·Ö£¬ÊÇÓÉa -»òb -΢¹Üµ°°×£¨a -orb -tubulin£©×é³ÉµÄÖпյÄÔ²Öù×´¶à¾ÛÌå¡£ºÍËüÃÇÏàÁ¬µÄ£¬ÊÇÎÞÊýµÄ΢¹ÜÏà¹Øµ°°×£¨MAPs£©£¬°üÀ¨MAP-2¡£
MAP-2ÊÇÄÔÖÐ×î·á¸»µÄMAP¡£Tau£¨Æä¿¹ÌåÊÇTauºÍTP70£©Ö÷Òª¶¨Î»ÓÚÖáË÷ÖУ¬Ò²ÊÇÒ»ÖÖMAP£¬µ«º¬Á¿½Ï
MAPÉÙ¡£

MAP-2ÊÇÒ»ÖÖÈÈÎȶ¨ÐÔµ°°×£¬ÔÚSDS¾Û±ûõ£°·Äý½ºµçӾʱ¾àÀëÇ¨ÒÆ½Ó½üµÄÒ»¶Ô¶àëÄ£¨Ô¼280KD£©£¬³ÆÎª
MAP-2aºÍMAP-2b¡£ÁíÍ⣬ÔÚÅßÌ¥ÆÚÄÔÖз¢ÏÖµÄÒ»¸ö70KDµÄMAP-2µÄ±äÒìÌ壬³ÆÎªMAP-2c¡£MAP-2bµÄ
È«³¤ cDNAÒÑÓÚ1988Äê´ÓÊóÄÔ¿Ë¡·ÖÀë³öÀ´£¬²¿·ÖƬ¶ÎÒàÔÚ1989Äê´ÓÈËÄÔÖлñµÃ¡£MAP-2bºÍMAP-2c
ÊÇÓÉͬһ»ùÒòת¼²úÎïµÄ²»Í¬Æ¬¶ÎÐγɡ£ÖÁÓÚMAP-2aÊÇ·ñÊÇͨ¹ý½»ÌæÁѽâ»òÕßÊÇÓÉMAP-2bת¼ºóÐÞÊÎ
¶øÀ´Éв»Çå³þ¡£Ò»°ã½«MAP-2aºÍMAP-2bͳ³ÆÎª¡°MAP-2¡±¡£

ÔÚMAP-2µÄ-COOHÄ©¶ËÓÐÈý¸ö²»ÍêÉÆµÄ°±»ùËáÖØ¸´×Ó£¬ËüÊÇÁ¬½Ó΢¹Üµ°°×£¨tubulin£©µÄ²¿Î»£¬¸Æµ÷µ°°×
£¨Calmodulin£©ÒàÔڴ˸½½üÁ¬½Óµ½MAP-2ÉÏ¡£MAP-2µÄ-NH2Ä©¶ËÊÇcAMPµÄ-R¢òÑǵ¥Î»½áºÏλµã¡£Ô¼1/3µÄ
¿ÉÈÜÐÔcAMP ÒÀÀµµÄµ°°×¼¤Ã¸ÔÚÄÔÖÐÓëMAP-2¹²´æ¡£ÔÚÌåÍ⣬MAP-2Óм«Ç¿µÄÓë×ÔÉíÐγɷ´Æ½ÐÐ
£¨antiparallel£©µÄ¶þ¾ÛÌåµÄÇãÏò¡£¾¡¹ÜÆäËü½áºÏλµãÉв»Çå³þ£¬µ«MAP-2»¹¿ÉÓëactin¡¢
NF¡¢ÏßÁ£Ìå¼°ÆäËü°ûÄڳɷֽáºÏ£¬ÕâЩÁ¬½ÓʹMAP-2´¦ÓÚÉñ¾­Ôª½á¹¹µÄ¶¯Á¦Ñ§¸Ä±äºÍ΢¹Ü·´Ó¦¹Ø¼üλÖá£

ϸ°ûÄÚµÄMAP-2Óкܶàλµã¿ÉÒÔ±»Á×Ëữ£¬ÕâЩλµãÒѱ»²ûÃ÷¿ÉÒÔÓÃÓÚµ÷½ÚMAP-2Óë΢¹ÜÒÔ¼°ÆäËüµ°°×
µÄÁ¬½Ó¡£·á¸»µÄÁ×Ëữ²¿Î»ºÍ¼¤Ã¸ÄÜÁ×ËữMAP-2£¬´Ó¶øÊ¹ºÜ¶àÒìÉúÐÎʽ¹²´æ¡£Êµ¼ÊÉÏ£¬¶ÔMAP-2µÄ¶þ
ά·ÖÎö±íÃ÷Ëü´æÔÚһϵÁеĵȵçµã¡£Õâ±íÃ÷MAP-2ÔÚ°ûÄÚµÄÁ×Ëữµ÷½ÚÊÇλµãÌØÒìÐÔ¶ø²»ÊÇ×ÜÌåÌØÒìÐÔ¡£
ÔÚ³ÉÊó£¬MAP-2¸ß¶È¼¯ÖÐÔÚÊ÷Í»¶øÔÚÖáË÷ÖÐȱÈç¡£MAP-2µÄÕâÖÖ·Ö¸ô·Ö²¼±íÃ÷ÁËMAP-2ÔÚÉñ¾­ÔªÖеķÇ
¶Ô³ÆÐÔ±í´ï¡£ÕâÖÖ·Ö²¼µÄ»úÖÆÊǾ«È·µÄ¶¨Î»µ÷¿ØºÍµ°°×µÄÈܽâ¹ý³Ì£¬ÕâÁ½¸öÒòËØ¹²Í¬µ÷½ÚMAP-2ÔÚÉñ¾­
Ôª°ûÌåÄÚµÄÌØÒìÐÔ·Ö²¼ºÍŨ¶ÈµÄ½á¹û¡£

MAP-2¶ÔÖáÍ»µÄÑÓÉìºÍ·ÖÖ§¡¢Ï¸°û·Ö»¯µÄÖÕÖ¹£¬¼´Éñ¾­Ôª³ÉÊìµÄ¹ý³ÌºÜ¹Ø¼ü¡£¶Ô³öÉúºó8¡«15ÌìµÄСÊó
½øÐÐXÏßÕÕÉ䣬µ¼ÖÂÆäСÄÔÆÑ¿ÏҰϸ°ûÒì³£µÄÀ­³¤µÄ¼â¶ËÊ÷Í»·ÖÖ§£¨ÔÚÍâ·Ö×Ӳ㣩¶ø²»ÊÇÏñÔÚÕý³£ÄÔÖÐ
ÄÇÑù½ôÁÚ°ûÌå¡£ÔÚ´ËŤÇúµÄÊ÷Í»ÖУ¬MAP-2µÄ·Ö²¼Æ«ÒƵ½Ô¶¶Ë£¬¼¯ÖÐÓÚÊ÷Í»µÄ·ÖÖ§Çø£»¶øÔÚÕý³£µÄÆÑ¿Ï
Ұϸ°ûÖÐMAP-2ÊǾùÔȵطֲ¼ÓÚÕû¸öÊ÷Í»ÖС£Õâ±íÃ÷MAP-2ÔÚÉñ¾­ÔªÄڵķֲ¼²¢²»½ö½öÈ¡¾öÓÚËüÊÇ·ñºÍ
΢¹ÜÁª½á£¬ÔÚ¼¸Ààϸ°ûÖêºÍԭʼϸ°ûÅàÑøÖУ¬MAP-2µÄ±í´ïºÍÉñ¾­ÖáÍ»µÄÉú³¤ºÍ·Ö²¼Ò»Ö¡£·ÖÖ§¹ã·ºµÄ
Éñ¾­ÔªMAP-2ÃâÒßÑôÐÔ¼«Ç¿£¬·ÖÖ§ÉÙµÄÉñ¾­ÔªµÄMAP-2ΪÈõÑôÐÔ¡£Õâ±íÃ÷ϸ°û·Ö»¯µÄÖÕÖ¹ºÍÉñ¾­ÖáÍ»·Ö
²¼¿ÉÄܶ¼ÒÀÀµMAP-2µÄ±í´ï¡£¾¡¹ÜÈç´Ë£¬²¢²»ÊÇËùÓеÄϸ°û¶¼ÐèÒªMAP-2Ôö¼ÓÀ´´ïµ½ÖáÍ»µÄÑÓÉì¡£ÔÚ·Ç
ѪÇå½éÖÊÖУ¬Éñ¾­Ä¸Ï¸°ûÁöϸ°û£¨N115»òS26¿Ë¡£©µÄ·Ö»¯ºÍÑÓÉì½öÐèÒªMAP-2µÄÇá¶ÈÓÕµ¼¡£

MAP-2¶ÔÊ÷Í»µÄÔÙÐγɺÍÍ»ÖáºóµÄ¸Ä±äÓÐ×÷Óã¬ÕâÖÖÇé¿ö·¢ÉúÔÚÌØÒìµÄËðÉ˺󣬵¥²àµÄ±ÇÄÚÒíÆ¤ÖÊ
(entorhinal cortex)ËðÉ˵¼ÖÂÔÚ³Ý×´»ØµÄÁ£Ï¸°ûÊ÷Í»ÖÐMAP-2µÄ·Ö²¼ºÍº¬Á¿±ä»¯£¬ÔÚMAP-2¼õÉٵIJ¿Î»£¬
Ê÷Í»±À½â£¬¶øÔÚMAP-2ÃâÒß·´Ó¦ÑôÐÔÔö¸ßµÄ²¿Î»°éÓÐÊ÷Í»µÄ³öÑ¿¡£ÓÐÖ¤¾Ý±íÃ÷£¬ÔÚËðÉ˺óµÄÔçÆÚ£¬
MAP-2ÔÚÉñ¾­ÔªÄÚ´ÓÉñ¾­Ö§ÅäÇøµ½·ÇÉñ¾­Ö§ÅäÇøÔÙ·Ö²¼£¬½Ó×ÅÔÚÊ÷Í»·¢ÉúÒ»¸ö³Ù·¢µÄ£¬ÆÕ±éµÄMAP-2
µÄÔö¼Ó¡£µ±Éñ¾­ÐÔ¼²²¡·¢Éúʱ£¬ÍùÍùÉæ¼°MAP-2µÄ±ä»¯¡£Alzeimer¡¯s²¡µÄÉñ¾­ÏËά²ø½á£¨NFTs£©
°üÀ¨¼¸¸öMAP-2µÄÃâÒß·´Ó¦Æ¬¶Î£¬ËùÓÐÕâЩƬ¶Î¶¼¶¨Î»ÓÚMAP-2µÄ-NHzÄ©¶Ë¡£¾«Éñ·ÖÁÑÖ¢¿É¼ûMAP-2
ºÍMAP-1bÒì³£¡£ MAP-2ÊÇÄÔ¶ÔȱÑõ²úÉú·´Ó¦µÄÒ»¸öÃô¸ÐÖ¸±ê¡£ÔÚÄÔËðÉ˵ÄÑо¿ÖÐ, ¶àÊÇÀûÓÃÄÔȱÑõ
µÄÄ£ÐͽøÐÐMAP-2µÄ¼ì²â¡£ÓÐ×ÊÁϱíÃ÷£¬ÔÚ½áÔúÓҲྱ×ܶ¯Âöºó£¬ÄÔ³ÖÐøÈ±Ñõ3min¼´µ¼ÖÂͬ²àº£Âí
CA1ÇøMAP-2Ͻµ£»Èçʱ¼ä¼ÌÐøÑÓ³¤£¬ÔòMAP-2µÄϽµ·¶Î§À©´óÖÁº£ÂíÆäËüÇøÓò£¬Æ¤ÖÊºÍÆäËüÄÔÇø¡£
ÔÝʱȱÑõ5min£¬1hºó¿É²âµÃMAP-2Ͻµ¡£È±Ñõʱ¼äÔ½³¤£¬MAP-2¶ªÊ§Ô½¶à¡£ÕâÀàÑо¿½á¹û±íÃ÷£¬MAP-2
¶ÔȱÑõ¼«¶ÈÃô¸Ð£¬ÊÇÄÔ¶ÔȱÑõ¡¢ËðÉ˲úÉú·´Ó¦µÄÒ»¸öÔçÆÚµÄ¡¢Ãô¸ÐµÄÖ¸±ê¡£MAP-2ÔÚÄÔËðÉË¡¢È±Ñõºó
µÄÂýÐԸıäÇé¿öÈçºÎ£¬ÉнÏÉÙÓÐÈËÉæ×ã¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡ ¡

b --µí·ÛÑùǰÌåµ°°×£¨b -amyloid protein precursor, b -APP£©(26-31)

°¢¶û´Äº£Ä¬Êϲ¡(Alzheimer¡¯s disease, AD)ÊÇ×îÆÕͨµÄÉñ¾­Í˱äÐÔ¼²²¡¡£¸Ã²¡»¼²¡ÂÊÔÚ65ËêÒÔÉϵÄÈËȺÖÐԼΪ5%-10%¡£ÔÚÃÀ¹ú£¬¸Ã²¡»¼ÕßÈË
Êý¾Í´ï¶þ°ÙÍòÈË×óÓÒ¡£¸Ã²¡µÄÌØÕ÷ÊǽøÐÐÐԵijմôºÍÌØ¶¨µÄÉñ¾­²¡Àíѧ¸Ä±ä£ºÏ¸°ûÍâµÄµí·ÛÑùµ°°×°ß¡¢
ϸ°ûÄÚµÄÉñ¾­ÏËά²ø½áºÍѪ¹Üµí·ÛÑùµ°°×µÄ³Á»ý¡£³¬Î¢½á¹¹Ï£¬µí·ÛÑùµ°°×°ßºÍѪ¹Üµí·ÛÑùµ°°×º¬ÓÐ
ÓÉ42-43¸ö°±»ùËáÑǵ¥Î»×é³ÉµÄ6¡«10nmµÄÖ±µÄϸ˿£¬ÕâЩÑǵ¥Î»¾ÍÊÇËùνb -»òA4-ëÄAP£¨b -AP£¬b µí·ÛÑùµ°°×£©¡£cDNA¿Ë¡±íÃ÷b -ëÄÊÇ×÷Ϊһ¸ö¸ü´óµÄǰÌåµ°°×·Ö×ÓµÄÒ»²¿
·Ö¶ø±»ºÏ³É¡£Õâ¸öǰÌåµ°°×·Ö×Ó¾ÍÊǦÂ-µí·ÛÑùǰÌåµ°°×£¨b -APP£©¡£b-APPÊÇÒ»ÖÖ¿çĤÌǵ°°×£¬Æä·Ö
×ÓÓÐ4ÖÖ²»Í¬µÄÐÎʽ£¬Ã¿Ò»ÐÎʽ¸÷°üº¬²»Í¬³¤¶ÈµÄ°±»ùËáÆ¬¶Î£º695£¬751£¬770ºÍ563¸ö£¬·Ö±ð³ÆÎªb APP 695£¬b APP 751£¬b APP 770ºÍb APP 563£¬ÆäÖÐb APP 563²»º¬b ëÄÇø¡£Æä»ùÒò¶¨Î»ÓÚÈËÀà
µÚ21ºÅȾɫÌ峤±Û£¬ÐòÁи߶ȱ£ÊØ£¬ÔÚÉñ¾­×éÖ¯ºÍ¶àÖÖ·ÇÉñ¾­×éÖ¯ÖÐÓбí´ï¡£b-APÓÉ39-43¸ö°±»ùËá
²Ð»ù¹¹³É£¬ÔÚÈËÌåÄÚÕý³£´æÔÚ£¬³¬¹ýÒ»¶¨Å¨¶Èʱ¼´²úÉúÉñ¾­¶¾ÐÔ¡£ÈçǰÊö£¬AD²¡»¼ÕßÄÔÖÐb -APŨ¶È
Éý¸ß¡£

b -APP »ùÒòת¼Éú³Éǰb -APP mRNA£¬ÔÚ²»Í¬²¿Î»ÇиîÉú³ÉËÄÖÖ²»Í¬³¤¶ÈµÄb -APP Mrna£¬·­ÒëºóÉú³É
ÉÏÊöËÄÖÖµ°°×£¬ËÄÖÖb -APP ÔÚÄԵIJ»Í¬²¿Î»¡¢²»Í¬Ï¸°ûÖеıí´ïÓвîÒì¡£Õý³£Éñ¾­ÔªÖÐÓÐb-APPµÄ±í´ï£¬
ͨ¹ý¿ìËÙÖὬÔËÊäÓɰûÌåÔËÍùÖáÍ»¼°Ê÷ͻĩ¶Ë¡£Õý³£ÄÔÄÚb -APPÖ÷ÒªÔÚb APÐòÁÐÄÚÁѽ⣬²úÉúÒ»¸ö11.5
KDµÄ·ÖÃÚÆ¬¶Î¶ø·ÇÍêÕûµÄb AP¡£b APPµÄÒì³£Áѽⳣ¼ûÓÚAlzheimer¡¯s²¡£¬´ËʱbAPPÔÚ¦ÂAP°±»ù
Ä©¶ËÁѽ⣬ÓàÏÂÍêÕûµÄb AP¹Ì¶¨ÓÚϸ°ûĤÉÏ¡£b APPÈçºÎת»¯Îªb APµÄ»úÖÆÉв»Çå³þ£¬ÓÐÈËÈÏ
ΪÐèÈÜøÌå²ÎÓë¡£µ¼ÖÂb -APP°±»ùËáÄ©¶Ë²¡ÀíÐÔ¶ÏÁѵÄÒòËØÖУ¬20%ÊÇ»ùÒòÍ»±ä£¬80%Óë»·¾³
Óйء£Ô¼30%µÄÖÂÃüÐÔ±ÕºÏÐÔÄÔËðÉË»¼ÕßÖпɷ¢ÏÖÓÐb -APP±í´ïÔöÇ¿¡£ÓÐÈ˶ÔÉ˺ó¼¸ÌìµÄb APPµ°°×¼°
ÆämRNA½øÐмì²â£¬·¢ÏÖÆäˮƽÉý¸ß¡£Gentleman¶ÔÖáË÷ËðÉ˺óµÄb APP½øÐÐÁËÑо¿£¬·¢ÏÖ
ËüÊǼì²âÖáË÷ËðÉ˵ÄÒ»¸öÓмÛÖµµÄÖ¸±ê¡£¶¯ÎïʵÑéÓÃÕë´ÌÔì³ÉÄÔËðÉË£¬·¢ÏÖÉ˺ó0.5hÔÚ´Ì´´ÖÜΧ¿É¼ûÖá
Ë÷Ö×ÕÍ£¬b -APP±í´ïÔöÇ¿£»6h¡«26hΪ±í´ï¸ß·åÆÚ£¬ÒÔºóÖð½¥Ï½µ¡£ÓÐѧÕßÈÏΪËðÉËÇøb-APPÔö¶àÊÇ
ÓÉÓÚÖὬÔËÊä±»×è¶Ï£¬b -APPÐî»ýµÄ½á¹û£»ÁíÒ»·½Ã棬b -APPÊÇÒ»Öֶ๦Äܵ°°×£¬ËðÉËϸ°ûÖбí
´ïÔöǿϵ¶ÔÍâ½ç´Ì¼¤µÄ·´Ó¦¡£Éñ¾­½ºÖÊϸ°û£¨Ö÷ÒªÊÇÐÇÐͽºÖÊϸ°û£©ÖÐÕý³£Çé¿öÏÂÓÐÉÙÁ¿b -APP±í´ï
£¨ÒÔb -APP751¡¢b -APP770ΪÖ÷£©£¬ËðÉ˺ó6h±í´ïÔöÇ¿£¬72h´ï¸ß·å£¬±í´ïÔöÇ¿¿É³ÖÐøÖÁÉ˺ó60Ìì¡£ÓÃb -APPÑо¿ÄÔËðÉ˵ķÖ×Ó»úÖÆÓÐÈçÏÂÓŵ㣺¢Ùb -APPÊÇÄÔËðÉ˺ó¿ìËٺϳɵķ´Ó¦µ°°×£¬ÔÚÄÔ
ËðÉ˺óÔçÆÚ¼´±í´ïÔöÇ¿¡£¢ÚÄÔ×éÖ¯²»Í¬²¿Î»²»Í¬Ï¸°ûb -APP±í´ïÓвîÒ죬ÔÚÄÔËðÉË·¢Õ¹¹ý³ÌÖÐÓÐ
Ò»¶¨µÄ±ä»¯¹æÂÉ£¬ÓÐÀûÓÚËðÉËʱ¼äµÄÍÆ¶Ï¡£¢Ûb -APPÐòÁи߶ȱ£ÊØ£¬¶¯ÎïʵÑé½á¹û¿ÉÓ¦ÓÃÓÚ·¨Ò½Ñ§¼ì°¸¡£
.
·µ»Ø·¨Ò½Ñ§½øÕ¹Óëʵ¼ù
.
·µ»ØËÄ´¨Ê¡·¨Ò½Ñ§»áÖ÷Ò³
.
·µ»Ø»ªÎ÷Ò½¿Æ´óѧ·¨Ò½Ñ§ÔºÖ÷Ò³
.¡¡